Furthermore, the findings of a meta-analysis suggest that SGLT2 inhibitors can significantly reduce all-cause mortality, cardiovascular death, and the incidence of first hospitalization for HF in patients with HFrEF and HFpEF (29). Here, SLC5A2 is linked to hydrops fetalis.